Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | HPGD | P15428 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16409554 | 0.86 | PLA2G4B (0.60) | KMT2AMEN1MAPK1NR1H4KAT6A | |
| SCHEMBL10575393 | 0.81 | HPGD (0.57) | KMT2AHPGDSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL20344652 | 0.81 | ALDH1A1 (0.51) | KMT2ASMN1; SMN2ALDH1A1MAPTMEN1 | |
| SCHEMBL7985855 | 0.81 | KAT6A (0.52) | KMT2AHPGDSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL5139133 | 0.81 | HPGD (0.68) | KMT2AHPGDSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL7984963 | 0.80 | KAT6A (0.51) | KMT2AHPGDSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL30129483 | 0.80 | LMNA (0.61) | KMT2AHPGDSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL29505934 | 0.80 | KMT2A (0.75) | KMT2AHPGDSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL29505938 | 0.80 | KMT2A (0.75) | KMT2AHPGDSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL307233 | 0.80 | KMT2A (0.75) | KMT2AHPGDSMN1; SMN2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3508484-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-07-10 | — | — | EP | disclosed |
| US-8772327-B2 | Phenylpropionic acid derivative and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2014-07-08 | — | — | US | disclosed |
| US-20130131134-A1 | PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF | MORITA KOHEI (JP) | 2013-05-23 | — | — | US | disclosed |
| US-8334314-B2 | Phenylpropionic acid derivative and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-12-18 | — | — | US | disclosed |
| US-20100093819-A1 | PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131134-A1 | PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF | PLA2G12A, PLA2G4A, PLA2G4B | KMT2A 1631/4885HPGD 164/4885SMN1; SMN2 3036/4885 |
| US-20100093819-A1 | PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF | PLA2G12A, PLA2G4A, PLA2G4B | KMT2A 1631/4885HPGD 164/4885SMN1; SMN2 3036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.